Altogether, these signaling mediators provide a complex network of positive and negative regulatory steps that ensure limited and quantitative action of TGFβ in diverse tissue types, while many of these mechanisms are misregulated in cancer cells [16]. The gene discussed is TGFB1; the disease is cancer.